Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Foamix Pharmaceuticals Ltd. (FOMX) since 2018 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Foamix Pharmaceuticals Ltd.. Table 2 shows the detailed insider transactions. This company's CIK number is 1606645.
Total stock buying since 2018: $488,306.
Total stock sales since 2018: $665,232.
Total stock option exercises since 2018: $113,150.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2019 | 13,440 | $50,534 | 76,525 | $252,477 | 182,500 | $113,150 |
| 2018 | 112,200 | $437,772 | 72,291 | $412,755 | 34,726 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2019-11 | 0 | $0 | 0 | $0 | 32,500 | $20,150 |
| 2019-10 | 0 | $0 | 0 | $0 | 90,000 | $55,800 |
| 2019-09 | 0 | $0 | 43,812 | $153,360 | 0 | $0 |
| 2019-08 | 0 | $0 | 7,049 | $23,050 | 60,000 | $37,200 |
| 2019-07 | 0 | $0 | 5,753 | $13,485 | 0 | $0 |
| 2019-05 | 0 | $0 | 10,600 | $27,666 | 0 | $0 |
| 2019-04 | 0 | $0 | 9,311 | $34,916 | 0 | $0 |
| 2019-03 | 13,440 | $50,534 | 0 | $0 | 0 | $0 |
| 2018-12 | 0 | $0 | 68 | $275 | 0 | $0 |
| 2018-11 | 112,200 | $437,772 | 11,156 | $45,373 | 0 | $0 |
| 2018-10 | 0 | $0 | 977 | $5,675 | 0 | $0 |
| 2018-09 | 0 | $0 | 67 | $379 | 0 | $0 |
| 2018-08 | 0 | $0 | 10,953 | $62,212 | 0 | $0 |
| 2018-07 | 0 | $0 | 978 | $4,987 | 1,616 | $0 |
| 2018-06 | 0 | $0 | 67 | $352 | 0 | $0 |
| 2018-05 | 0 | $0 | 6,164 | $31,368 | 0 | $0 |
| 2018-04 | 0 | $0 | 978 | $4,967 | 0 | $0 |
| 2018-03 | 0 | $0 | 883 | $5,408 | 0 | $0 |
| 2018-01 | 0 | $0 | 40,000 | $251,759 | 33,110 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2019-11-04 | Hirsch Stanley (Director) | Option Ex | 32,500 | .62 | 20,150 |
| 2019-10-15 | Hirsch Stanley (Director) | Option Ex | 90,000 | .62 | 55,800 |
| 2019-09-10 | Hadar Ilan (CFO & Country Manager) | Sale | 34,392 | 3.50 | 120,372 |
| 2019-09-09 | Hadar Ilan (CFO & Country Manager) | Sale | 9,420 | 3.50 | 32,988 |
| 2019-08-26 | Kazanchyan Anna (Director) | Sale | 7,049 | 3.27 | 23,050 |
| 2019-08-13 | Hirsch Stanley | Option Ex | 60,000 | .62 | 37,200 |
| 2019-07-15 | Kazanchyan Anna (Director) | Sale | 808 | 2.31 | 1,866 |
| 2019-07-01 | Harsch Mutya (CLO and General Counsel) | Sale | 639 | 2.35 | 1,501 |
| 2019-07-01 | Domzalski David (CEO) | Sale | 3,355 | 2.35 | 7,884 |
| 2019-07-01 | Stuart Iain (Chief Scientific Officer) | Sale | 951 | 2.35 | 2,234 |
| 2019-05-20 | Kazanchyan Anna (Director) | Sale | 10,600 | 2.61 | 27,666 |
| 2019-04-01 | Harsch Mutya (CLO and General Counsel) | Sale | 2,519 | 3.75 | 9,446 |
| 2019-04-01 | Domzalski David (CEO) | Sale | 5,096 | 3.75 | 19,110 |
| 2019-04-01 | Stuart Iain (Chief Scientific Officer) | Sale | 1,696 | 3.75 | 6,360 |
| 2019-03-05 | Wiley Matthew T. (Chief Commercial Officer) | Buy | 13,440 | 3.76 | 50,534 |
| 2018-12-03 | Domzalski David (CEO) | Sale | 68 | 4.05 | 275 |
| 2018-11-28 | Schwartz Aharon | Buy | 12,200 | 3.88 | 47,372 |
| 2018-11-27 | Schwartz Aharon | Buy | 50,000 | 3.92 | 195,800 |
| 2018-11-26 | Schwartz Aharon | Buy | 50,000 | 3.89 | 194,600 |
| 2018-11-19 | Domzalski David (CEO) | Sale | 5,036 | 3.90 | 19,640 |
| 2018-11-19 | Howard Alvin D (VP Regulatory) | Sale | 3,375 | 3.90 | 13,162 |
| 2018-11-08 | Domzalski David (CEO) | Sale | 2,062 | 4.58 | 9,443 |
| 2018-11-08 | Stuart Iain (SVP R&D) | Sale | 683 | 4.58 | 3,128 |
| 2018-10-01 | Elliott Russell P. (VP Drug Development) | Sale | 142 | 5.81 | 825 |
| 2018-10-01 | Domzalski David (CEO) | Sale | 601 | 5.81 | 3,491 |
| 2018-10-01 | Howard Alvin D (VP Regulatory) | Sale | 234 | 5.81 | 1,359 |
| 2018-09-04 | Domzalski David (CEO) | Sale | 67 | 5.67 | 379 |
| 2018-08-08 | Domzalski David (CEO) | Sale | 8,238 | 5.68 | 46,791 |
| 2018-08-08 | Stuart Iain (SVP R&D) | Sale | 2,715 | 5.68 | 15,421 |
| 2018-07-13 | Hirsch Stanley | Option Ex | 1,616 | .00 | 0 |
| 2018-07-02 | Elliott Russell P. (VP Drug Development) | Sale | 142 | 5.10 | 724 |
| 2018-07-02 | Domzalski David (CEO) | Sale | 602 | 5.10 | 3,070 |
| 2018-07-02 | Howard Alvin D (VP Regulatory) | Sale | 234 | 5.10 | 1,193 |
| 2018-06-01 | Domzalski David (CEO) | Sale | 67 | 5.26 | 352 |
| 2018-05-13 | Hirsch Stanley | Sale | 6,164 | 5.09 | 31,368 |
| 2018-04-02 | Elliott Russell P. (VP Drug Development) | Sale | 142 | 5.08 | 721 |
| 2018-04-02 | Domzalski David (CEO) | Sale | 602 | 5.08 | 3,058 |
| 2018-04-02 | Howard Alvin D (VP Regulatory) | Sale | 234 | 5.08 | 1,188 |
| 2018-03-02 | Elliott Russell P. (VP Drug Development) | Sale | 817 | 6.14 | 5,016 |
| 2018-03-01 | Domzalski David (CEO) | Sale | 66 | 5.95 | 392 |
| 2018-01-15 | Shirvan Mitchell (VP Innovation & Discovery) | Option Ex | 562 | .00 | 0 |
| 2018-01-15 | Schuz David (VP IP) | Option Ex | 562 | .00 | 0 |
| 2018-01-15 | Hazot Yohan (VP Pharmaceutical Development) | Option Ex | 562 | .00 | 0 |
| 2018-01-15 | Hadar Ilan (CFO & Country Manager) | Option Ex | 562 | .00 | 0 |
| 2018-01-15 | Eini Meir | Option Ex | 1,125 | .00 | 0 |
| 2018-01-11 | Eini Meir | Sale | 5,000 | 6.33 | 31,660 |
| 2018-01-10 | Eini Meir | Sale | 5,000 | 6.04 | 30,225 |
| 2018-01-09 | Eini Meir | Sale | 5,000 | 6.10 | 30,520 |
| 2018-01-08 | Eini Meir | Sale | 5,000 | 6.17 | 30,850 |
| 2018-01-05 | Eini Meir | Sale | 5,000 | 6.58 | 32,880 |
| 2018-01-04 | Eini Meir | Sale | 5,000 | 6.68 | 33,410 |
| 2018-01-03 | Eini Meir | Sale | 5,000 | 6.26 | 31,309 |
| 2018-01-02 | Eini Meir | Sale | 5,000 | 6.18 | 30,905 |
| 2018-01-01 | Elliott Russell P. (VP Drug Development) | Option Ex | 1,372 | .00 | 0 |
| 2018-01-01 | Domzalski David (CEO) | Option Ex | 5,948 | .00 | 0 |
| 2018-01-01 | Shirvan Mitchell (VP Innovation & Discovery) | Option Ex | 2,745 | .00 | 0 |
| 2018-01-01 | Schuz David (VP IP) | Option Ex | 2,745 | .00 | 0 |
| 2018-01-01 | Hazot Yohan (VP Pharmaceutical Development) | Option Ex | 4,575 | .00 | 0 |
| 2018-01-01 | Hadar Ilan (CFO & Country Manager) | Option Ex | 5,032 | .00 | 0 |
| 2018-01-01 | Eini Meir | Option Ex | 5,032 | .00 | 0 |
| 2018-01-01 | Howard Alvin D (VP Regulatory) | Option Ex | 2,288 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises of FOMX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Foamix Pharmaceuticals Ltd. (symbol FOMX, CIK number 1606645) see the Securities and Exchange Commission (SEC) website.